Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-06-14
2005-06-14
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Vector, per se
C435S235100, C435S069100, C435S045000, C435S456000, C435S325000, C435S366000, C424S093100, C424S093200, C424S093600
Reexamination Certificate
active
06905873
ABSTRACT:
Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.
REFERENCES:
patent: 4740463 (1988-04-01), Weinberg et al.
patent: 4920209 (1990-04-01), Davis et al.
patent: 4980289 (1990-12-01), Temin et al.
patent: 5055400 (1991-10-01), Lo et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5362623 (1994-11-01), Vogelstein et al.
patent: 5527676 (1996-06-01), Vogelstein et al.
patent: 5532220 (1996-07-01), Lee et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 6143290 (2000-11-01), Zhang et al.
patent: 6410010 (2002-06-01), Zhang et al.
patent: 6511847 (2003-01-01), Zhang et al.
patent: 6677312 (2004-01-01), Vogelstein et al.
patent: 0174608 (1985-09-01), None
patent: 0351585 (1989-06-01), None
patent: 0 390 323 (1990-10-01), None
patent: 0475623 (1991-08-01), None
patent: 2688514 (1993-09-01), None
patent: 04-009338 (1992-01-01), None
patent: 8-508879 (1996-09-01), None
patent: WO 91/05180 (1990-05-01), None
patent: WO 90/10448 (1990-09-01), None
patent: WO 91/15580 (1991-10-01), None
patent: WO 93/03769 (1993-03-01), None
patent: WO 93/19191 (1993-09-01), None
patent: WO 93 25224 (1993-12-01), None
patent: WO 94 06910 (1994-03-01), None
patent: WO 94/08026 (1994-04-01), None
patent: WO 94/10323 (1994-05-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 94/26914 (1994-11-01), None
patent: WO 95/02697 (1995-01-01), None
patent: WO 95/11301 (1995-04-01), None
patent: 95 11984 (1995-05-01), None
patent: WO 95/14101 (1995-05-01), None
patent: WO 95/14102 (1995-05-01), None
patent: WO 95/23867 (1995-09-01), None
patent: WO 95 30002 (1995-11-01), None
patent: WO 94/24297 (1997-10-01), None
Berkner, Current Topics in Microbiology and Immunology, 1992, vol. 158, pp. 39-66.
Kaufman, Methods in Enzymology, 1990, vol. 185, pp. 487-511.
Bacchetti et al., International Journal of Oncology, vol. 3 pp. 781-788, Oct. 22, 1993.
Casey, G., et al., “Growth Suppression of Human Breast Cancer Cells by the Introduction of a Wild-Type p53 Gene,”Oncogene, 6(10) :1791-1797.
Gomez-Foix, A., et al., “Adenovirus-mediated Transfer of the Muscle Glycogen Phosphorylase Gene into Hepatocytes Confers Altered Regulation of Glycogen Metabolism,”The Journal of Biological Chemistry, 267 (35) :25129-25134, 1992.
Hollstein, M., et al., “p53 Mutations in Human Cancers,”Science, 253:49-53, 1991.
Jaffe, H.A., et al., “Adenovirus-mediated in vivo Gene Transfer and Expression in Normal Rat Liver,”Nature Genetics, 1:372-378, 1992.
Le Gal La Salle, G., et al., “An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain,”Science, 259:988-990, 1993.
Mercer, W. Edward, “Cell Cycle Regulation and the p53 Tumor Suppressor Protein.”Critical Reviews in Eukaryotic Gene Expression, 2(3) :251-263, 1992.
Montenarh, M., “Biochemical, Immunological, and Functional Aspects of the Growth-Suppressor/Oncoprotein p53,”Critical Reviews in Oncogenesis, (3) :233-256, 1992.
Prevec, L., et al. “Use of Human Adenovirus-based Vectors for Antigen Expression in Animals,”J. Gen. Virol., 70:429-434, 1989.
Rosenfeld, M., et al., “Adenovirus-Mediated Transfer of a Recombinant α1-Antitrypsin Gene to the Lung Epithelium in Vivo,”Science, 252:431-434, 1991.
Rosenfeld, M., et al., “In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium,”Cell, 68:143-155, 1992.
Stratford-Perricaudet, L., “Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector,”Human Gene Therapy, 1:241-256, 1990.
Stratford-Perricaudet, L., “Gene Transfer Into Animals: the Promise of Adenovirus,”Human Gene Transfer, 219:51-61, 1991.
Stratford-Perricaudet, L., “Feasibility of Adenovirus-Mediated Gene Transfer in vivo,”Bone Marrow Transplantation, 9 (Suppl.1) :151-152, 1992.
Stratford-Perricaudet, L., “Widespread Long-term Gene Transfer to Mouse Skeletal Muscles and Heart,”J. Clin. Invest., 90:626-630, 1992.
Weinberg, R., “Tumor Suppressor Genes,”Science, 254:1138-1146, 1991.
Zhang & Roth, “Propagation of Recombinant p53 Adenovirus and Evaluation of its Effect on Human Lung Cancer Cell Lines,”The Fourth Meeting on the Molecular Basis of Cancer, Jun. 1993.
Co-pending U.S. patent application No. 08/459,713.
Co-pending U.S. patent application No. 09/413,109.
Co-pending U.S. patent application No. 09/447,681.
Co-pending U.S. patent application No. 10/180,895.
Felgner et al., “Lipfection: a highly efficient, lipid-mediated DNA-transfection procedure,”Proc. Natl. Acad. Sci. USA, 84:7413-7417, 1987.
Gjerset et al., “Dominant Effect of Transduced Wild-type p53 over endogenous mutant p53 in sensitizing tumor cells to therapy,”Proceedings of the Am. Assoc. for Cancer Res., 36:21, 1995. (Abstract 123).
Eaves et al., “The biology of normal and neoplatic stem cells in CML,” Chronic Myeloid Leukemia, 2ndInt'l Conference, Bologma, Italy, Oct. 4-7, 1992. FromLeukemia and Lymphoma, 11:245-253 (1993).
Gomez-Navarro et al., “Gene Therapy for Cancer,”European Journal of Cancer, 35:867-885, 1999.
Green, “When the Products of Oncogenes and Anti-Oncogenes Meet,”Cell, 56:1-3, 1989.
Harper et al., “the p21 cdk-interacting protein cip1 is a potent inhibitor of g1 cyclin-dependent kinases,”Cell, 75:805-816, 1993.
Huber et al., “Retroviral-Mediated Gene Therapy for the Treatment of Hepatocellular Carcinoma: An Innovative Approach for Cancer Therapy,”Proc. Natl. Acad. Sci Usa, 88:8039-8043, 1991.
In: Comprehensive Textbook of Oncology, vol. 1, 2nd.Ed., Williams & Wilkins, Publ., pp. 477, 527-536, 565-568, 590-594, 607-612, 1986.
In: Comprehensive Textbook of Oncology, vol. 2, 2nd. Ed., Williams & Wilkins, Publ., pp. 1098, 1138-1140, 1170, 1329, 1368, 1569-1572, 1986.
Kastan “p53 and other molecular controls of the response to DNA damage.”Adv. Exp. Med. Biol., 339:295-296, 1993.
Klinken et al., “Transcriptional and Post-Transcriptional Regulation of C-MYC C-MYB and p53 During Proliferation and Differentiation of Muring Erythroleukemia Cells Treated with DFMO and DMSO,”Exp. Cell Res.,178:185-198, 1988.
Kriegler et al., In: Gene Transfer and Expression: a laboratory manual, 1990.
Lord et al., “Macrophage Inflammatory Protein: Its Characteristics, Biological Properties and Role in the Regulation of Haemopoiesis,”International J. of Hemaiology, 57:197-206, 1993.
Marx, “Cell Death Studies Yield Cancer Clues,”Science, 259:760-761 (1993).
Muzyczka, “Use of adeno-assiiated virus as a general transduction vector for mammalian cells,”Microbiol. Immunol.,158:98-129, 1992.
Orazi et al., “Frequent p53 overspression in therapy related mylodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopaies,”Mod. Path., 6:521-525, 1993.
Ryan et al., “Cell Cycle Analysis of p53-Induced cell Death in Murine Erythroleukemia Cells,”Mol. Cell. Biol., 13:711-719, 1993.
Singleton and Sainsbury, Dictionary of Microbiology and Molecular Biology, 2nd Ed., John Wiley & Sons, Publ., pp. 591 and 920, 1987.
Stedman's Medical Dictionary, 25th Ed., Wiliams & Wilkins, Publ., p.245, 1990.
Stratagene catalogue, p. 39, 1988.
Fan et al., “p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents,”Cancer Res., 54(22):5824-5830, 1994.
Fujiwara et al., “Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-media
Roth Jack A
Zhang Wei-Wei
Board of Regents , The University of Texas System
Fulbright & Jaworski L.L.P.
Guzo David
LandOfFree
Recombinant p53 adenovirus methods and compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant p53 adenovirus methods and compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant p53 adenovirus methods and compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3520316